A Registry and Biospecimen Collection to Advance the Diagnosis and Care of Patients with Glomerular Diseases

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 14-007389
    Sponsor Protocol Number: CureGN

About this study

The purpose of this registry is to establish a database of patients diagnosed with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or immunoglobulin A nephropathy (IgAN), to advance the diagnosis and care of patients with glomerular diseases.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria

  • Diagnosis of MCD, FSGS, MN, or IgAN on first diagnostic kidney biopsy, per specified pathology definitions
    • First diagnostic kidney biopsy within 5 years of study enrollment
    • Access to first kidney biopsy report and/or slides
  • All ages
  • Willing to comply with study requirements, including intention to fully participate in protocol-specified follow-up at a clinical study site
  • Informed consent and, where age appropriate, informed assent 

 Exclusion Criteria

  • ESKD, defined as chronic dialysis or kidney transplant 
  • Institutionalized
  • Solid organ or bone marrow transplant recipient at time of first kidney biopsy
  • Diagnosis of any of the following at the time of first diagnostic kidney biopsy
    • Diabetes mellitus 
    • Systemic lupus erythematosus
    • HIV infection
    • Active malignancy, except for non-melanoma skin cancer
    • Active Hepatitis B or C infection, defined as positive viral load
  • For the NEPTUNE cohort study with one of the core diagnoses in CureGN (MCD, FSGS, MN, IgA nephropathy) exclusion criteria may be waived to allow for long term follow-up via CureGN study

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Fernando Fervenza, M.D., Ph.D.

Open for enrollment

Contact information:

Vladimir Chernitskiy

(507)255-0231

Chernitskiy.Vladimir@mayo.edu

.
CLS-20304853

Mayo Clinic Footer